Cytos Biotechnology AG reported a smaller loss in the third quarter and first nine months of 2012 following a reorganisation and refinancing that left the Swiss company with a reduced pipeline. The lead product is an asthma immunotherapy.
Cytos Biotechnology AG reported a smaller loss in the third quarter and first nine months of 2012 following a reorganisation and refinancing that left the Swiss company with a reduced pipeline. The lead product is an asthma immunotherapy.